Fundraising Fox
/Companies
Sign in

GRI BIO

NASDAQ: GRI

La Jolla, US · Delaware corporation

Find your way into GRI BIO

Sign up to see every warm intro you have to GRI BIO

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the GRI BIO team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Grib Bio is developing a pipeline of NKT cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases by targeting early steps in the inflammatory cascade. It operates in the biotechnology and drug development sector.

Biotech

Founders & leadership

WM
Walter Marc HertzFounder
LKLeanne Kelly
Leanne KellyExecutiveLeanne Kelly is Chief Financial Officer/Vice President of Finance at GRI BIO, a biotechnology company developing NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases. She holds a CPA credential and has prior experience in financial reporting, SEC compliance, Sarbanes-Oxley implementation, fundraising, and building finance department infrastructure for early-stage companies.
WM
W. Marc HertzPresident, Chief Executive Officer and Director
VK
Vipin KumarChief Scientific Officer
AA
Albert AgroChief Medical Officer
AA
Albert ArgoNamed on SEC filing
VK
Vipin Kumar ChaturvediNamed on SEC filing

Board

RR
Roelof RongenBoard director
DS
David SzekeresBoard director
CS
Camilla SimpsonBoard director
DB
David BakerBoard director

Reported raises · per SEC filings

Form D private placements

$16.3M disclosed across 2 rounds · 2023–2024

▶$762.2KraisedOct 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Roelof RongenDirector
  • David SzekeresDirector
  • Walter Marc HertzExecutive Officer, Director
  • Camilla SimpsonDirector
  • Leanne KellyExecutive Officer
  • David BakerDirector
Offering amount
$762.2K
Amount sold
$762.2K
Sales commissions
$61K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Oct 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.6MraisedApr 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David BakerDirector
  • Albert ArgoExecutive Officer, Director
  • Camilla V. SimpsonDirector
  • Walter Marc HertzExecutive Officer, Director
  • Roelof RongenDirector
  • Vipin Kumar ChaturvediExecutive Officer, Director
  • David SzekeresDirector
  • Leanne KellyExecutive Officer, Director
Offering amount
$15.6M
Amount sold
$15.6M
First sale
Apr 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does GRI BIO do?
Grib Bio is developing a pipeline of NKT cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases by targeting early steps in the inflammatory cascade. It operates in the biotechnology and drug development sector.
Who founded GRI BIO?
GRI BIO was founded by Walter Marc Hertz.
How much funding has GRI BIO raised?
GRI BIO has disclosed $16.3M raised across 2 rounds.
Where is GRI BIO headquartered?
GRI BIO is headquartered in La Jolla, US.